Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;20(7):1087-1099.
doi: 10.2174/0115734099266308231108112058.

Mechanism of Polygala-Acorus in Treating Autism Spectrum Disorder Based on Network Pharmacology and Molecular Docking

Haozhi Chen  1 , Changlin Zhou  1 , Wen Li  1 , Yaoyao Bian  1   2
Affiliations

Mechanism of Polygala-Acorus in Treating Autism Spectrum Disorder Based on Network Pharmacology and Molecular Docking

Haozhi Chen et al. Curr Comput Aided Drug Des. 2024.

Abstract

Background: Recent epidemic survey data have revealed a globally increasing prevalence of autism spectrum disorders (ASDs). Currently, while Western medicine mostly uses a combination of comprehensive intervention and rehabilitative treatment, patient outcomes remain unsatisfactory. Polygala-Acorus, used as a pair drug, positively affects the brain and kidneys, and can improve intelligence, wisdom, and awareness; however, the underlying mechanism of action is unclear.

Objectives: We performed network pharmacology analysis of the mechanism of Polygala-Acorus in treating ASD and its potential therapeutic effects to provide a scientific basis for the pharmaceutical's clinical application.

Methods: The chemical compositions and targets corresponding to Polygala-Acorus were obtained using the Traditional Chinese Medicine Systematic Pharmacology Database and Analysis Platform, Chemical Source Website, and PharmMapper database. Disease targets in ASD were screened using the DisGeNET, DrugBank, and GeneCards databases. Gene Ontology functional analysis and metabolic pathway analysis (Kyoto Encyclopedia of Genes and Genomes) were performed using the Metascape database and validated via molecular docking using AutoDock Vina and PyMOL software.

Results: Molecular docking analysis showed that the key active components of Polygala- Acorus interacted with the following key targets: EGFR, SRC, MAPK1, and ALB. Thus, the key active components of Polygala-Acorus (sibiricaxanthone A, sibiricaxanthone B tenuifolin, polygalic acid, cycloartenol, and 8-isopentenyl-kaempferol) have been found to bind to EGFR, SRC, MAPK1, and ALB.

Conclusion: This study has preliminarily revealed the active ingredients and underlying mechanism of Polygala-Acorus in the treatment of ASD, and our predictions need to be proven by further experimentation.

Keywords: Network pharmacology; Polygala-Acorus; autism spectrum disorder; drugs and disease; molecular docking; molecular mechanism..

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest, financial or otherwise.

Figures

Fig. (1)
Fig. (1)
Flowchart of the mechanism of action of Polygala–Acorus in the treatment of ASD.
Fig. (2)
Fig. (2)
Venn diagram of common genes between Polygala–Acorus and autism spectrum disorder.
Fig. (3)
Fig. (3)
Protein-protein interaction network of potential target genes of Polygala–Acorus in treating autism spectrum disorder.
Fig. (4)
Fig. (4)
Topological analysis of protein-protein interaction network. A larger circle and darker color indicate a high genetic value.
Fig. (5)
Fig. (5)
Gene ontology function analysis.
Fig. (6)
Fig. (6)
Kyoto encyclopedia of genes and genomes pathway enrichment.
Fig. (7)
Fig. (7)
Active components-targets-pathways-disease networks.
Fig. (8)
Fig. (8)
Molecular docking results (kcal·mol-1).
Fig. (9)
Fig. (9)
Molecular docking details.
See this image and copyright information in PMC

References

    1. Hirota T., King B.H. Autism spectrum disorder. JAMA. 2023;329(2):157–168. doi: 10.1001/jama.2022.23661. - DOI - PubMed
    1. Zhang, X.Y.; Kong, Y.M.; Ma, B.X.; Dang, W.L.; Zhou, R.Y.; Shi, W.L. Research progress in the neurobiology of animal models of autism spectrum disorder. Acta Laboratorium Animalis Scientia Sinica. 2022;30(08):1141–1149.
    1. Maenner M.J., Warren Z., Williams A.R., Amoakohene E., Bakian A.V., Bilder D.A., Durkin M.S., Fitzgerald R.T., Furnier S.M., Hughes M.M., Ladd-Acosta C.M., McArthur D., Pas E.T., Salinas A., Vehorn A., Williams S., Esler A., Grzybowski A., Hall-Lande J., Nguyen R.H.N., Pierce K., Zahorodny W., Hudson A., Hallas L., Mancilla K.C., Patrick M., Shenouda J., Sidwell K., DiRienzo M., Gutierrez J., Spivey M.H., Lopez M., Pettygrove S., Schwenk Y.D., Washington A., Shaw K.A. Prevalence and characteristics of autism spectrum disorder among children aged 8 years — autism and developmental disabilities monitoring network, 11 sites, United States, 2020. MMWR Surveill. Summ. 2023;72(2):1–14. doi: 10.15585/mmwr.ss7202a1. - DOI - PMC - PubMed
    1. Zhou H., Xu X., Yan W., Zou X., Wu L., Luo X., Li T., Huang Y., Guan H., Chen X., Mao M., Xia K., Zhang L., Li E., Ge X., Zhang L., Li C., Zhang X., Zhou Y., Ding D., Shih A., Fombonne E., Zheng Y., Han J., Sun Z., Jiang Y., Wang Y. Prevalence of autism spectrum disorder in China: A nationwide multi-center population-based study among children aged 6 to 12 years. Neurosci. Bull. 2020;36(9):961–971. doi: 10.1007/s12264-020-00530-6. - DOI - PMC - PubMed
    1. Wang L., Ding Y.R., Wang S.C. Experience of WANG Shou-chuan in treating and differentiating autism with syndrome of deficiency of both heart and spleen. Zhonghua Zhongyiyao Zazhi. 2018;33(8):3393–3395.

MeSH terms

Substances